Airlock allows quick and contamination-free transfer.

Press Release Summary:




Available in stand-alone and integrated versions, Fast Air Lock ISS 1000 enables accelerated, contamination-free transfer of pharmaceutical equipment into and out of isolators. It operates independently from status of main filling isolator and can transfer microbiological materials. Evaporation process and loading unit reduce cycle times to 20 min, and transfer cart enables ergonomic loading/unloading of lock. Other features include SafeVAP bio-decontamination system and HEPA filters.



Original Press Release:



Bosch Presents Fast Air Lock ISS 1000 for Quick and Contamination-Free Transfer



New development underlines leading position
  • Cycle times of only 20 minutes depending on load
  • Available as stand-alone and integrated version
  • 100th Bosch isolator sold to international pharma customer

    At Achema 2012 in Frankfurt/Main, Germany, Bosch Packaging Technology introduces the new Fast Air Lock ISS 1000 at its booth (C70, C72) in hall 3.1. The new machine was developed for the fast and contamination-free transfer of pharmaceutical equipment into and out of isolators. It operates independently from the status of the main filling isolator and can, for instance, transfer microbiological materials. With an especially efficient evaporation process and an optimized loading unit, cycle times of this new development have been significantly reduced. The external door of the lock can be opened while the isolator is in operation. Bio-decontamination can also occur independently from the operating condition of the main isolator.

    The transfer cart enables a very ergonomic loading and unloading of the lock. This leads to optimized loading patterns and consequently to minimized transfer times. Depending on the load, the ISS 1000 only needs approximately 20 minutes per cycle.

    The new ISS 1000 is equipped with the well-proven bio-decontamination system Bosch SafeVAP, which ensures a safe evaporation of hydrogen peroxide. Air supply is generated from the ambient space while the exhaust air is conducted to the outside of the building. The air within the lock is conducted by Hepa filters.

    The ISS 1000 is available as integrated or stand-alone version. The inner door of the integrated version opens directly into the main isolator to which it is firmly connected. Instead of the inner door, the stand-alone unit has an aseptic interface in the form of an RTP (rapid transfer port) system.

    In this version, the connected container and the lock are decontaminated simultaneously. Due to the independent container transfer, several filling lines can be supported with only one ISS 1000. The transfer container is loaded by means of a glove which is integrated into the door.

    System competence for isolator technology
    For more than 20 years, Bosch Packaging Technology has developed isolators for the pharmaceutical industry. Compared to conventional cleanroom production, isolators offer higher product quality, lower operating costs and a safe accomplishment of longer production cycles.

    Bosch isolator systems are available for all machine types processing ampoules, vials, cartridges and ready-to-use syringes.

    Bosch underlines its pioneering position in the field of isolator technology with the current sale of its 100th isolator to an international pharmaceutical customer. At Achema, this isolator is showcased with an FLC filling and sealing machine and will be delivered to the customer after the trade fair.

    The FLC fills up to 24,000 vials and infusion bottles per hour and is available for cleanroom conditions and as isolator version. The isolator is the smallest, safest and most economical solution for a sterile room.

    At the customer's site, the isolator will be used in combination with an entire vial filling and sealing line for highly potent pharmaceuticals. The filling machine is connected upstream to a washing machine and a sterilization tunnel. The filled vials are loaded into a freeze dryer and transported to a capping machine after lyophilisation. The isolator ensures a sterile and contamination-free process from the end of the sterilization tunnel to the loading station of the freeze dryer and to the capping machine. Apart from product protection, the safety of the operating personnel is given top priority in the processing of highly potent agents.

    The Bosch division Packaging Technology, based in Waiblingen (Germany), is one of the leading suppliers in the field of processing and packaging technology. In more than 15 countries worldwide it develops and produces complete solutions for the pharmaceutical, food and confectionery industries. The comprehensive service portfolio completes the package. The worldwide sales and service network offers local contacts. More information at www.boschpackaging.com

    The Bosch Group is a leading global supplier of technology and services. According to preliminary figures, more than 300,000 associates generated sales of 51.4 billion euros in the areas of automotive and industrial technology, consumer goods, and building technology in fiscal 2011. The Bosch Group comprises Robert Bosch GmbH and its more than 350 subsidiaries and regional companies in some 60 countries. If its sales and service partners are included, then Bosch is represented in roughly 150 countries. This worldwide development, manufacturing, and sales network is the foundation for further growth. Bosch spent more than 4 billion euros for research and development in 2011, and applied for over 4,100 patents worldwide. With all its products and services, Bosch enhances the quality of life by providing solutions which are both innovative and beneficial.

    The company was set up in Stuttgart in 1886 by Robert Bosch (1861-1942) as "Workshop for Precision Mechanics and Electrical Engineering." The special ownership structure of Robert Bosch GmbH guarantees the entrepreneurial freedom of the Bosch Group, making it possible for the company to plan over the long term and to undertake significant up-front investments in the safeguarding of its future. Ninety-two percent of the share capital of Robert Bosch GmbH is held by Robert Bosch Stiftung GmbH, a charitable foundation. The majority of voting rights are held by Robert Bosch Industrietreuhand KG, an industrial trust.

    The entrepreneurial ownership functions are carried out by the trust. The remaining shares are held by the Bosch family and by Robert Bosch GmbH.

  • All Topics